AI Article Synopsis
- Ulcerative colitis (UC) and Crohn's disease (CD) are chronic inflammatory bowel diseases that can affect heart rhythms, with studies indicating a risk for serious cardiac arrhythmias in adult IBD patients.
- A study involving 36 pediatric patients with IBD (UC and CD) and 36 matched controls evaluated heart electrical activity through electrocardiograms, finding significantly longer P-wave and QT interval dispersion in IBD patients.
- The research suggests that children with IBD, even in remission, may be at risk for serious heart rhythm problems over time, highlighting the importance of monitoring these patients.
Article Abstract
Ulcerative colitis (UC) and Crohn's disease (CD) are chronic inflammatory bowel diseases (IBD) with unclear underlying aetiologies. Severe cardiac arrhythmias have been emphasised in a few studies on adult IBD patients. This study aimed to investigate the alteration of the P-wave and QT interval dispersion parameters to assess the risk of atrial conduction and ventricular repolarisation abnormalities in pediatric IBD patients. Thirty-six IBD patients in remission (UC: 20, CD: 16) aged 3-18 years and 36 age- and sex-matched control patients were enrolled in the study. Twelve-lead electrocardiograms were used to determine durations of P-wave, QT, and corrected QT (QTc) interval dispersion. Transthoracic echocardiograms and 24-hour rhythm Holter recordings were obtained for both groups. The P-wave dispersion, QT dispersion, and QTc interval dispersion (Pdisp, QTdisp, and QTcdisp) were significantly longer in the patient group. The mean values of Pminimum, Pmaximum, and QTcminimum were significantly different between the two groups. The echocardiography and Holter monitoring results were not significantly different between the groups. Furthermore, no differences in these parameters were detected between the CD and UC groups. Results suggest that paediatric IBD patients may carry potential risks for serious atrial and ventricular arrhythmias over time even during remission.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339525 | PMC |
| http://dx.doi.org/10.1155/2017/6960810 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Prevalence of bronchiectasis in patients with inborn errors of immunity].
Rev Alerg Mex
December 2024
Pediatra con subespecialidad en Alergia e Inmunología Clínica; jefe del servicio y profesor titular de la especialidad de Alergia e Inmunología Clínica, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco.
Objective: To establish the prevalence of bronchiectasis, correlate the IgG IV or SC immunoglobulin dose and serum IgG levels with the total Bhalla score and the severity of bronchiectasis and associate serum IgG levels with the development of pulmonary infectious processes in patients with diagnosis of innate errors of immunity.
Methods: A descriptive, observational, cross-sectional study with patients over 18 years of age diagnosed with IBD. Clinical records and computed axial tomography were reviewed.
Early Onset Active Inflammatory Bowel Disease Is Associated With Psychiatric Comorbidities: A Multi-Network Propensity-Matched Cohort Study.
Crohns Colitis 360
January 2025
Digestive Health Institute, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Background: Psychiatric disease burden in patients with Inflammatory bowel disease (IBD) has risen substantially over the past few decades. However, there is limited data on the relationship between IBD disease activity and the incidence of psychiatric comorbidities. We sought to conduct a population-based study to investigate the impact of early onset disease activity in newly diagnosed IBD patients on psychiatric disease diagnoses and medication usage.
View Article and Find Full Text PDFFeatures, Treatments, and Therapeutic Outcomes of Peristomal versus Non-Peristomal Pyoderma Gangrenosum in 45 Patients with Inflammatory Bowel Disease: A Single-Institution Study, 2002 through 2021.
Skinmed
January 2025
Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA.
Pyoderma gangrenosum (PG) is the second most common skin manifestation reported in patients with inflammatory bowel disease (IBD). We performed a single-institution, retrospective study to summarize the clinical features and examine effective treatment regimens and outcomes of PG in IBD patients. We identified 45 patients who presented to our institute between January 1, 2002 and December 31, 2021 with the following criteria: (1) diagnosed with an active PG (ICD9: 686.
View Article and Find Full Text PDFFrequency of Spondyloarthritis Symptoms Among U.S. Patients with Inflammatory Bowel Disease: A Cross-sectional Multi-Center Study.
Arthritis Care Res (Hoboken)
January 2025
Stanford University School of Medicine, Palo Alto, CA, USA.
Objective: Spondyloarthritis (SpA) is the most common extraintestinal manifestation of inflammatory bowel disease (IBD). The application of screening tools to detect SpA in patients with IBD may lead to earlier recognition of SpA and affect treatment decisions.
Methods: A combination of two previously described SpA screening questionnaires, DETAIL and IBIS-Q, was administered to consecutive patients with IBD attending IBD specialty clinics in six U.
[Application of advanced treatment in chronic inflammatory bowel diseases].
Inn Med (Heidelb)
January 2025
Medizinischen Klinik I, Agaplesion Markus Krankenhaus, Wilhelm-Epstein-Str. 4, 60431, Frankfurt/Main, Deutschland.
Background: The treatment options for chronic inflammatory bowel diseases (IBD) have been greatly expanded due to a better understanding of the underlying pathogenesis. A total of five classes of advanced treatment are available.
Objective: A practical overview of advanced treatment of IBD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!